Verification of Autoantibody Serology Tests: Practical Considerations for the Clinical Laboratory

Subvisible particle analysis is a key predictor of protein drug stability and a key formulation, quality metric. However, current methods use large volumes of precious protein solutions and are labor- and time-intensive, making this data inaccessible during late-stage candidate screening or early in formulation. Moreover, regulatory agencies are tightly enforcing subvisible particle content in biopharma formulations at unprecedented levels, making early detection of subvisible particles, like protein aggregates, a key analytical priority.

The microbiome continuously shapes its environment through a complex set of interactions, and the microbial flora within and outside the human body has an essential relationship to an organism’s health status.

To slow or reverse the effects of climate change, there is promise in development of biotechnology innovations that enhance the adaptation, resilience, preservation, and restoration of natural and managed ecosystems.

BIO One-on-One Partnering™ is the most efficient way to do business in the biotech and pharma industry without traveling all over the world. Our system makes it easy to search for and identify potential partners and request meetings with prospective biotech investors and senior business development executives. Did you know that partnering attendees average 13 scheduled BIO One-on-One Partnering meetings at BIO?